Yourgene have worked to provide a commentary on a range of different topics and content relevant to the product and service porfolio that Yourgene provides. We aspire that these articles are relevant, informative, educational and add value. Enjoy.
Cystic Fibrosis Newborn Screening in the NHS – 1 June 2023
In the NHS, Yourgene® Cystic Fibrosis Lite is used as part of a clinical pathway following upfront immunoreactive trypsinogen (IRT) testing. Active trypsin enzyme helps the body digest proteins in the gastrointestinal tract and is produced from the inactive proenzyme version, Trypsinogen.
International Women’s Day 2023 – 8 March 2023
Yourgene Health is today unveiling the Yourgene Microdeletions Plugin Accelerator phase, following a successful pilot project with LifeStrands Genomics. This Accelerator represents a new era in Yourgene’s approach to delivery of NIPT testing solutions, with a focus on ‘Collaboration to Perform’. Working as a partnership, rather than the traditional laboratory/manufacturer relationship, represents a shared commitment to ensuring high-quality and performance-driven testing, ultimately delivering better outcomes for patients.
Ranger® Revolution – LightBench® Detect is here! – 20 June 2022
The wait is over! Yourgene Health are proud to today reveal the Ranger® Revolution in the form of the LightBench® Detect; the latest addition to our Ranger® Technology portfolio. We’ve worked closely with our clinical laboratory partners to develop a size selection instrument that is optimised for improving the performance of liquid biopsy workflows, most notably non-invasive prenatal testing (NIPT). The LightBench® Detect addresses a pressing need for NIPT.
Collaboration to Perform: Yourgene Microdeletions Plugin Accelerator – 24 May 2022
Yourgene Health is today unveiling the Yourgene Microdeletions Plugin Accelerator phase, following a successful pilot project with LifeStrands Genomics. This Accelerator represents a new era in Yourgene’s approach to delivery of NIPT testing solutions, with a focus on ‘Collaboration to Perform’. Working as a partnership, rather than the traditional laboratory/manufacturer relationship, represents a shared commitment to ensuring high-quality and performance-driven testing, ultimately delivering better outcomes for patients.
Exclusion criteria for NIPT explained – 15 February 2022
The IONA ® test is a non-invasive prenatal test (NIPT) for pregnant women which estimates the risk of a fetus having Down’s syndrome (Trisomy 21), Edwards’ syndrome (Trisomy 18) and Patau’s syndrome (Trisomy 13). The test is performed by analysing cell-free placental-fetal DNA from a maternal blood sample. The test is suitable for women who are at least 10 weeks pregnant, prior to ten weeks there is a risk that there would be insufficient placental-fetal cell
International Women and Girls in Science Day 2022
Here at Yourgene Health, we are very proud that a large proportion of our genomic technologies and services business, including senior leadership and laboratory managers, are powerful women. We believe it is important to showcase the impressive range of talent we are lucky to have, including our women and girls in science.
In light of the International Day of Women and Girls in Science, we would like to place a spotlight on a few members
New Year, New Regulations – 19 January 2022
The ‘New Year’s resolution’ is a tradition almost all of us are familiar with, in which a person resolves to accomplish a personal goal, continue good habits or change undesirable ones all with the intention of self-improvement. A study of over 800 million activity data points on the exercise platform Strava found that today, January 19th, is the most common day for a New Year’s resolution to be abandoned…
Behind the scenes: Adapting diagnostic services during a pandemic – 11 November 2021
The diagnostic testing business has always been dynamic and opportunistic , but nothing could have stretched the definition of these 2 words like a pandemic.
Since the launch of Yourgene Genomic Services 6 months into this global pandemic – born from a legacy, well established NIPT service laboratory, a modest acquisition, and an unprecedented national genomic testing demand, we have vastly expanded our testing capacity by converting every spare inch of underutilised office space created by remote…
Overprescribing within the NHS – 02 November 2021
“Good for you, good for us but is it good for everybody?” – Overprescribing within the NHS – October 2021
The NHS is currently the 5th largest global employer; with over 1.3m employees and receiving around 10% of the UK Government’s annual spending. It is estimated that the NHS deals with 336 million ‘patient visits’ per year, – many of whom will receive some form of at least one ‘prescription’ per visit and at a current charge in…
